Erythrodermic psoriasis induced by bupropion

Matos-Pires, Eugénia; Campos, Sara; Mendes‐Bastos, Pedro; João, A.; Fernandes, Carolina

doi:10.1111/jdv.13876

Cited by 10 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…New drugs have been associated with psoriasis, particularly oncological and immunological targeted therapies 1 . Several cases of bupropion‐associated psoriasis have been reported, including one related to naltrexone/bupropion 3‐5 . However, the exact mechanism by which bupropion triggers psoriasis is unknown.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patch test–proven delayed‐type hypersensitivity from naltrexone/bupropion possibly eliciting psoriasis

et al. 2021

View full text Add to dashboard Cite

A 25-year-old woman with a history of childhood atopic dermatitis and allergic rhinitis was referred for patch testing due to an 18-month history of significant dermatitis involving the face, eyelids, and scalp.Her symptoms began as pruritic papules along the, hairline and scalp, which progressed to edematous red scaly plaques involving the eyelids, forehead, and cheeks. Previous treatments included oral prednisone and topical preparations of the following: multiple corticosteroids, diphenhydramine, erythromycin, and mupirocin. Notably, the patient suspected a "hypoallergenic" moisturizer, Resta Skin Crème-The Melting Moisturizer (SteadMed, Fort Worth, Texas), had exacerbated her symptoms when applied to the face and eyelids. She was patch tested to the North American Contact Dermatitis Group (NACDG) screening series and several supplemental series including corticosteroids, personal care product series (general, shampoo/soap), preservatives, emulsifiers, and multiple personal items. All allergens were occluded for 2 days. Day (D)4 patch testing demonstrated a ++ reaction to her Resta Skin Crème (tested "as is") and a + reaction to Arbonne Speak Volume Mascara (Arbonne International,

show abstract

Section: Discussionmentioning

confidence: 99%

“…1 Several cases of bupropionassociated psoriasis have been reported, including one related to naltrexone/bupropion. [3][4][5] However, the exact mechanism by which bupropion triggers psoriasis is unknown. Bupropion has also been documented to induce severe cutaneous drug reactions, such as Stevens-Johnson syndrome and AGEP.…”

Section: Discussionmentioning

confidence: 99%

Patch test–proven delayed‐type hypersensitivity from naltrexone/bupropion possibly eliciting psoriasis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It is important to recognize and address the causes of erythrodermic psoriasis, including rapid withdrawal of systemic immunosuppressive therapy, underlying systemic infections, or drug reactions [ 3 , 6 ]. This is the fourth report and sixth case of bupropion-associated erythrodermic psoriasis [ 1 , 7 , 8 ]. In addition to erythroderma, Stevens-Johnson syndrome and morbilliform drug eruption have also occurred following bupropion initiation, both with concomitant psoriasis exacerbation secondary to koebnerization [ 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

Erythrodermic Psoriasis Exacerbated by Bupropion

Foss¹,

Nyckowski²,

Steffes³

2021

Cureus

View full text Add to dashboard Cite

Erythroderma is a rare, potentially life-threatening presentation of psoriasis that can be triggered by medication reactions. Bupropion is indicated for major depressive disorder (Wellbutrin®, GlaxoSmithKline, Research Triangle Park, NC), smoking cessation (Zyban®, GlaxoSmithKline, Research Triangle Park, NC), and weight loss (when in formulation with naltrexone ER; Contrave®, Orixegen Therapeutics, La Jolla, CA). Bupropion can exacerbate psoriasis, however, this is an under-recognized side effect of the medication, particularly in the United States. We report a case of bupropion-induced erythrodermic psoriasis in a 62year-old female who was prescribed the medication for depression. Due to the common comorbidities of depression, obesity, and tobacco abuse in psoriatic patients, all for which treatment with bupropion is indicated, it is important for physicians to be aware of the potential for a life-threatening medication reaction in this patient population.

show abstract

“…Наиболее часто псориатическая эритродермия развивается на фоне уже существующего псориаза [1,2]. К триггерам псориатической эритродермии относят инфекционные заболевания, эмоциональный стресс, чрезмерную инсоляцию, нерациональное применение и отмену лекарственных препаратов, в частности применение системных кортикостероидов, ингибиторов факторов некроза опухоли-альфа, топических ретиноидов, чрезмерное применение топических кортикостероидов, резкую отмену применения метотрексата [1,[3][4][5][6][7].…”

Section: обоснованиеunclassified

Psoriatic erythroderma: comparative patient profile and association with psoriatic arthritis

Витальевна

2023

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Background: Psoriatic erythroderma is rare and the most severe form of psoriasis characterized by involvement of 80-90% of body surface area. Aims: to compare clinical and demographic characteristics of patients with psoriasis, depending on presence of psoriatic erythroderma in medical history; to assess the association between psoriatic arthritis and a history of psoriatic erythroderma. Materials and methods: patients aged 18 years and older with a duration of psoriasis of 10 years, from the psoriasis patients registry were included. Comparison of continuous quantitative variables was performed using t-test or Mann-Whitney U-test. The 2 test or Fisher's exact test was used to compare qualitative binary variables. The odds ratio of psoriatic arthritis in patients with and without a history of psoriatic erythroderma was calculated, unadjusted and adjusted for other independent variables. Results: The number of patients included in the analysis was 1,870. A history of psoriatic erythroderma (PE) had 227 (12.1%) of them. There were no significant differences in patient age at inclusion to the registry (47.113.1 years vs. 47.713.3 years), and prevalence of PE among men and women (12.6% vs. 11. 4%). Higher prevalence of arterial hypertension (47.9% vs 32.7%), angina pectoris (6.4% vs. 1.9%), myocardial infarction (3. 2% vs. 1.0%), biliary dyskynesia (14.3% vs. 3.9%), fatty liver (12.2% vs. 7.7%), cholelithiasis (8. 6% vs. 3.6%), and toxic liver disease (2.2% vs. 0.5%) among patients with vs without history of PE was found. Psoriatic arthritis was diagnosed in 67.0% patients with a history of psoriatic erythroderma. The odds of having psoriatic arthritis in patients with a history of psoriatic erythroderma were 4 times higher than in patients without erythroderma: 4.043 [2.975-5.493]. When adjusted for sex, age, duration of psoriasis, and body mass index, the odds ratio and statistical significance were maintained: 4.064 [2.939-5.619]. Conclusions: compared to patients without PE those with a history of psoriatic erythroderma have a greater comorbidity burden: a higher prevalence of cardiovascular diseases, diseases of the liver and biliary tract. A significant association between psoriatic arthritis and a history of PE was established.

show abstract

Erythrodermic psoriasis induced by bupropion

Cited by 10 publications

References 9 publications

Patch test–proven delayed‐type hypersensitivity from naltrexone/bupropion possibly eliciting psoriasis

Patch test–proven delayed‐type hypersensitivity from naltrexone/bupropion possibly eliciting psoriasis

Erythrodermic Psoriasis Exacerbated by Bupropion

Psoriatic erythroderma: comparative patient profile and association with psoriatic arthritis

Contact Info

Product

Resources

About